R&D institute SRI International has a received contract worth up to $100 million to develop technologies for treating excessive radiation exposure.
SRI Biosciences, a division of SRI International, will provide facilities, expertise, and capabilities to advance the development of countermeasures to mitigate or treat acute radiation syndromes, delayed effects from acute radiation exposure, and internal radionuclide contamination. The funding is part of a seven-year contract with the U.S. National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID).
SRI Biosciences also will provide supportive services to the NIAID's radiation and nuclear medicine countermeasures program to advance the development of technologies like biodosimetric approaches to determine radiation exposure.
SRI will perform R&D studies to advance technologies toward eventual U.S. Food and Drug Administration approval or licensure, as well as to provide the administrative foundation to facilitate and coordinate these activities in partnership with the NIAID.
